SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

07 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

22 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

14 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

23 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

08 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

28 дек 2023 09:15:21 Источник Nasdaq GlobeNewswire

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

18 дек 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

08 дек 2023 08:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

07 ноя 2023 16:05:01 Источник Nasdaq GlobeNewswire

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

24 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023

19 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting

12 окт 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

03 окт 2023 08:30:00 Источник Nasdaq GlobeNewswire

Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023

11 сен 2023 16:06:00 Источник Nasdaq GlobeNewswire

Sight Sciences Appoints Matt Link as Chief Commercial Officer

11 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference

30 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

03 авг 2023 16:05:01 Источник Nasdaq GlobeNewswire

Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023

20 июл 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye

20 июл 2023 08:30:00 Источник Nasdaq GlobeNewswire

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)

21 июн 2023 08:30:00 Источник Nasdaq GlobeNewswire